1-(4-((6-(3-hydroxyphenyl)-8-morpholinoimidazo[1,2-a]pyrazin-2-yl)methyl)-piperazin-1-yl)ethanone | 1252594-48-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 英文名称: 1-(4-((6-(3-hydroxyphenyl)-8-morpholinoimidazo[1,2-a]pyrazin-2-yl)methyl)-piperazin-1-yl)ethanone
• 英文别名: (4-((6-(3-hydroxyphenyl)-8-morpholinoimidazo[1,2-a]pyrazin-2-yl)methyl)-piperazin-1-yl)ethanone；(4-((6-(3-Hydroxyphenyl)-8-morpholinoimidazo[1,2-a]pyrazin-2-yl)methyl)piperazin-1-yl)ethanon；1-[4-[[6-(3-Hydroxyphenyl)-8-morpholin-4-ylimidazo[1,2-a]pyrazin-2-yl]methyl]piperazin-1-yl]ethanone
• CAS: 1252594-48-1
• 化学式: C₂₃H₂₈N₆O₃
• 分子量: 436.514
• InChiKey: HQSUDCCNUKPXGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  86.4
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS
  申请人：Centro Nacional de Investigaciones Oncológicas (CNIO)

  公开号：EP2419429A1

  公开（公告）日：2012-02-22
• IMIDAZOPYRAZINES AS INHIBITORS OF PROTEIN KINASES
  申请人：Centro Nacional de Investigaciones Oncológicas (CNIO)

  公开号：EP2419429B1

  公开（公告）日：2014-03-26
• US8778935B2
  申请人：——

  公开号：US8778935B2

  公开（公告）日：2014-07-15
• [EN] IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS<br/>[FR] IMIDAZOPYRAZINES POUR UNE UTILISATION EN TANT QU'INHIBITEURS DE KINASE
  申请人：CT NAC DE INVESTIGACIONES ONCO

  公开号：WO2010119264A1

  公开（公告）日：2010-10-21

  There is provided compounds of formula (I), wherein R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
• [EN] COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT<br/>[FR] COMBINAISONS D'INHIBITEURS DE PI3K AVEC UN SECOND AGENT ANTITUMORAL
  申请人：CT NAC INVESTIGACIONES ONCOLOGICAS CNIO

  公开号：WO2012052745A1

  公开（公告）日：2012-04-26

  There is provided combinations comprising (A) a compound of formula (I), wherein R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, together with (B) one or more therapeutics agents/treatments known to be useful in the treatment of diseases such as cancer or a proliferative disease, which combinations are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.